Bosh sahifa22Z • FRA
add
Zealand Pharma A/S
Yopilish kursi
55,38 €
Kunlik diapazon
54,22 € - 57,00 €
Yillik diapazon
51,76 € - 130,40 €
Bozor kapitalizatsiyasi
30,47 mlrd DKK
Oʻrtacha hajm
112,00
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
CPH
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (DKK) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 8,09 mln | -46,37% |
Joriy xarajat | 414,72 mln | 55,72% |
Sof foyda | -335,34 mln | -46,66% |
Sof foyda marjasi | -4,14 ming | -173,48% |
Har bir ulushga tushum | -4,75 | -28,03% |
EBITDA | -401,08 mln | -60,93% |
Amaldagi soliq stavkasi | 0,41% | — |
Balans
Jami aktivlari
Jami passivlari
| (DKK) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 8,54 mlrd | 163,42% |
Jami aktivlari | 9,12 mlrd | 154,33% |
Jami passivlari | 813,74 mln | 8,67% |
Umumiy kapital | 8,31 mlrd | — |
Tarqatilgan aksiyalar | 70,69 mln | — |
Narxi/balansdagi bahosi | 0,47 | — |
Aktivlardan daromad | -10,93% | — |
Kapitaldan daromad | -11,49% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (DKK) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -335,34 mln | -46,66% |
Operatsiyalardan naqd pul | -500,79 mln | -123,89% |
Sarmoyadan naqd pul | 554,62 mln | 140,23% |
Moliyadan naqd pul | -791,00 ming | -100,04% |
Naqd pulning sof oʻzgarishi | 50,12 mln | -77,53% |
Boʻsh pul | -398,07 mln | -169,78% |
Haqida
Zealand Pharma A/S is a Danish biotechnology research company, which designs and develops peptide-based medicines, mainly focusing on metabolic diseases like diabetes and obesity. The company's head office is situated in Søborg near Copenhagen, and it has close to 200 employees. In 2018, they opened a subsidiary in the US. Zealand Pharma forms part of the Danish-Swedish life science cluster Medicon Valley. Wikipedia
Tashkil etilgan
1-apr, 1997
Xodimlar soni
385
